![Martin John Shott](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Martin John Shott
Chairman at European Pharmaceuticals Group Ltd.
Martin John Shott active positions
Companies | Position | Start | End |
---|---|---|---|
European Pharmaceuticals Group Ltd.
![]() European Pharmaceuticals Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Cardinal Health, Inc., European Pharmaceuticals Group Ltd. is a holding British company with investments in subsidiary undertakings engaged in pharmaceuticals. The company is based in Romford, UK. European Pharmaceuticals Group was acquired by The Intercare Group Plc from Groenwondt Beheer Bv on September 17, 1999 for $40.03 million. | Chairman | 14/09/2010 | - |
Royal Pharmaceutical Society of Great Britain
![]() Royal Pharmaceutical Society of Great Britain Miscellaneous Commercial ServicesCommercial Services The Royal Pharmaceutical Society of Great Britain provides expertise and support to its member pharmacists. The private company is based in Great Britain. Alex MacKinnon has been the CEO of the British company since 2010. | Corporate Officer/Principal | 14/09/2010 | - |
Career history of Martin John Shott
Former positions of Martin John Shott
Companies | Position | Start | End |
---|---|---|---|
Lers-Synthelabo | Corporate Officer/Principal | - | - |
Innovata Biomed Ltd.
![]() Innovata Biomed Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Philip Morris International, Inc., Innovata Biomed Ltd. engages in the research, development, and commercialization of respiratory drug delivery technologies. The company is based in Edinburgh, UK. | Chief Tech/Sci/R&D Officer | - | - |
NOVARTIS AG | Corporate Officer/Principal | - | - |
VECTURA GROUP | Chief Operating Officer | 06/09/2009 | 24/11/2011 |
Corporate Officer/Principal | 24/11/2011 | - |
Training of Martin John Shott
The University of Nottingham | Doctorate Degree |
Statistics
International
United Kingdom | 6 |
Switzerland | 2 |
France | 2 |
Operational
Corporate Officer/Principal | 4 |
Chief Operating Officer | 1 |
Chief Tech/Sci/R&D Officer | 1 |
Sectoral
Health Technology | 4 |
Commercial Services | 3 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
NOVARTIS AG | Health Technology |
Private companies | 5 |
---|---|
Vectura Group Ltd.
![]() Vectura Group Ltd. Pharmaceuticals: MajorHealth Technology Vectura Group Ltd. engages in the provision of pharmaceutical development. Its activities include research, development, and commercialization of novel therapeutic products. The company operates through the following segments: Switzerland, United Kingdom, Germany, United States of America, and France. Vectura Group was founded by David Anthony Gough in 1997 and is headquartered in Chippenham, the United Kingdom. | Health Technology |
Royal Pharmaceutical Society of Great Britain
![]() Royal Pharmaceutical Society of Great Britain Miscellaneous Commercial ServicesCommercial Services The Royal Pharmaceutical Society of Great Britain provides expertise and support to its member pharmacists. The private company is based in Great Britain. Alex MacKinnon has been the CEO of the British company since 2010. | Commercial Services |
Innovata Biomed Ltd.
![]() Innovata Biomed Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Philip Morris International, Inc., Innovata Biomed Ltd. engages in the research, development, and commercialization of respiratory drug delivery technologies. The company is based in Edinburgh, UK. | Commercial Services |
European Pharmaceuticals Group Ltd.
![]() European Pharmaceuticals Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Cardinal Health, Inc., European Pharmaceuticals Group Ltd. is a holding British company with investments in subsidiary undertakings engaged in pharmaceuticals. The company is based in Romford, UK. European Pharmaceuticals Group was acquired by The Intercare Group Plc from Groenwondt Beheer Bv on September 17, 1999 for $40.03 million. | Health Technology |
Lers-Synthelabo |
- Stock Market
- Insiders
- Martin John Shott
- Experience